Premium
KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in prostate cancer cells than in normal prostate cells
Author(s) -
Lu Wei,
Zhou Daixing,
Glusman Gustavo,
Utleg Angelita G.,
White James T.,
Nelson Peter S.,
Vasicek Thomas J.,
Hood Leroy,
Lin Biaoyang
Publication year - 2006
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20382
Subject(s) - pseudogene , prostate cancer , prostate , biology , gene , cancer research , androgen , carcinogenesis , cancer , genetics , endocrinology , genome , hormone
BACKGROUND Fifteen human tissue kallikrein ( KLK ) genes have been identified as a cluster on chromosome 19. KLK expression is associated with various human diseases including cancers. Noncoding RNAs such as PCA3/DD3 and PCGEM1 have been identified in prostate cancer cells. METHODS Using massively parallel signature sequencing (MPSS) technology, RT‐PCR, and 5′ rapid amplification of cDNA ends (RACE), we identified and cloned a novel gene that maps to the KLK locus. RESULTS We have characterized this gene, named as KLK31P by the HUGO Gene Nomenclature Committee, as an unprocessed KLK pseudogene. It contains five exons, two of which are KLK‐derived while the rest are “exonized” interspersed repeats. KLK31P is expressed abundantly in prostate tissues and is androgen regulated. KLK31P is expressed at lower levels in localized and metastatic prostate cancer cells than in normal prostate cells. CONCLUSIONS KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that may play a role in prostate carcinogenesis or maintenance. Prostate 66: 936–944, 2006. © 2006 Wiley‐Liss, Inc.